Pharmaceutical Impurity Control – Corporate Training

Description

Pharmaceutical Impurity Control – Corporate Training

This training program provides a comprehensive understanding of impurity identification, control strategies, and regulatory expectations to ensure product quality, safety, and compliance throughout the product lifecycle.

Key Learning Areas:

• Impurity Control Strategy (QbD Approach)
  Implementing a Quality by Design (QbD)-based control strategy covering manufacturing process controls, in-process testing, specification setting, stability studies, and timely corrective actions to ensure consistent product quality and data integrity.
• Classification of Impurities
  Understanding different types of impurities, including known and unknown impurities, degradation products, genotoxic and mutagenic impurities, and stereoisomeric impurities.
• Risk Assessment & Critical Impurity Identification
  Conducting risk-based assessments to identify critical impurities based on toxicity, exposure levels, and potential impact on patient safety.
• Analytical Detection & Method Validation
  Applying robust analytical techniques for impurity detection and quantification, ensuring appropriate sensitivity (LOD/LOQ), specificity, and resolution from the active pharmaceutical ingredient (API), along with full method validation.
• Specification Setting & Regulatory Justification
  Establishing scientifically justified impurity limits based on safety data, ICH guidelines, and trend analysis, ensuring alignment with regulatory expectations.

Note: A detailed training module and customized curriculum can be provided upon request.